https://thetruthaboutketosis.com/
The Ketogenic diet or Keto Diet is not a diet fad or a new diet. Although over the last few years the Keto Diet has received a lot of attention, both positive and negative, the Keto Diet has been around for almost one hundred years.
Keto was created by doctors in 1924 to treat epilepsy, and more recently has been studied as a treatment for diabetes.
Keto really works and has unbelievable health benefits, besides weight loss, that you will notice in a short period of time.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
The Epilepsy Foundation launched the “Talk About It!” public service announcement featuring actor Greg Grunberg to raise awareness and encourage open dialogue about epilepsy and seizures. Greg, best known for his roles on Heroes, Alias, and Felicity, has an adult son who lives with epilepsy, a condition that affects nearly 3 million Americans. The Epilepsy Foundation and Greg teamed up for this PSA, sponsored by Sunovion Pharmaceuticals Inc., to drive much needed conversation about epilepsy – bringing the condition out of the shadows and honoring a community that deserves better awareness and understanding. More information about the PSA and initiative can be found by visiting the Epilepsy Foundation at epilepsy.com.
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
As the holiday season approaches and people begin planning their decorations, Cyberonics, Inc. is urging them to maintain the momentum of Epilepsy Awareness Month in November by incorporating purple lights into their holiday décor.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7378051-cyberonics-launches-mylifeisbright-campaign-healthyandbright-promotion-epilepsy-awareness-month-shine-purple-lights/
WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, today released Marijuana on Main Street, a special report that provides an in-depth look at the debate over medical marijuana. As numerous states consider bills to legalize medical marijuana, WebMD surveyed nearly 3,000 consumers and Medscape surveyed more than 1,500 doctors about their attitudes regarding legalization, marijuana as a potential treatment option, and the perceived risks and benefits of its use to help shed light on this evolving issue.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7040258-webmd-medscape-medical-marijuana-report
Upsher-Smith Laboratories, Inc., today announced the addition of the topic Sleep Disorders and Epilepsy to its epilepsy-focused educational website, Epilog.us. The site now features a review of the relationship between epilepsy and sleep disorders.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59872-epilog-us-expert-discussion-comorbidity-of-sleep-disorders-and-seizures
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, Epilog.us [http://www.Epilog.us], now features a panel discussion of leading experts on the role of rational polytherapy in the treatment of patients with epilepsy, led by Dr. Barry Gidal, Professor of Pharmacy and Neurology/Division Chair, University of Wisconsin. Dr. Gidal also brings forward discussion on the mechanism of action of specific antiepileptic drugs (AEDs). Additional topics include: AED pharmacokinetics; patient adherence and AEDs; and drug interactions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59891-upsher-smith-epilog-us-pharmacodynamics-of-antiepileptic-drugs-aeds
Approximately 1.5 million women and girls in the United States have epilepsy, of which nearly 500,000 are women of childbearing age. Treating women with epilepsy, especially women of childbearing age, presents significant challenges to physicians. Epilog.us [http://www.epilog.us], Upsher-Smith Laboratories, Inc’s [http://www.upsher-smith.com] epilepsy-focused educational website, discusses these challenges and provides professional insight by some of the epilepsy community’s most respected physicians including Dr. Cynthia Harden, Chief of the Comprehensive Epilepsy Care Center, North Shore University Hospital and Long Island Jewish Medical Center, and Dr. Christopher Skidmore, Director of Neurology Residency/Assistant Professor of Neurology, at Jefferson Medical College of Thomas Jefferson University.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59306-upsher-smith-epilog-website-challenges-in-managing-women-with-epilepsy
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that subscribers to Epilog.us can now access the latest information related to Practice Management & Epilepsy at http://www.Epilog.us. Led by Dr. Aatif Husain, Director of the Clinical Neurophysiology Fellowship, Professor of Medicine, Division of Neurology, Duke University Medical Center, and Dr. John Stern, Co‐Director of the Seizure Disorder Center and Professor of Neurology at the David Geffen School of Medicine at UCLA, areas of focus include: the importance of billing code accuracy; commonly utilized billing codes in epilepsy and neurology; and epilepsy quality measures from the American Academy of Neurology (AAN).
To view Multimedia News Release, go to http://www.multivu.com/mnr/58062-upsher-smith-epilog-us-practice-management-epilepsy-resources-available
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, http://www.Epilog.us, has been expanded to include thought-leader commentary on issues related to Epilepsy and Comorbidities. The newly updated website will make its debut at the 64th Annual American Academy of Neurology Meeting in New Orleans on April 23 – 26, 2012, at the Upsher-Smith exhibit, booth number 128.
TO view Multimedia News Release, go to http://www.multivu.com/mnr/55934-upsher-smith-expands-epilog-us-on-epilepsy-comorbidities
